Increased expression of microRNA miR‐326 in type 1 diabetic patients with ongoing islet autoimmunity

Sebastiani, Guido; Grieco, Fabio Arturo; Spagnuolo, Isabella; Galleri, Letizia; Cataldo, Dorica; Dotta, Francesco

doi:10.1002/dmrr.1262

Cited by 121 publications

(95 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Elevated expression of miR-326 was found in peripheral blood lymphocytes of T1D patients with ongoing islet autoimmunity (Sebastiani et al 2011). Clinically, Nielsen et al (2012) showed the upregulation of twelve serum miRNAs (miR-152, miR30a-5p, miR-181a, miR-24, miR-148a, miR-210, miR-27a, miR-29a, miR-26a, miR-27b, miR-25, and miR-200a) in T1D patients; particularly they found that miR-25 was negatively associated with b-cell function.…”

Section: Pkb (Akt) Signaling (Insulin Sensitivity)mentioning

confidence: 99%

Application of microRNAs in diabetes mellitus

Chen¹,

Lan²,

Roukos³

et al. 2014

Journal of Endocrinology

107

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are small molecules negatively regulating gene expression by diminishing their target mRNAs. Emerging studies have shown that miRNAs play diverse roles in diabetes mellitus. Type 1 diabetes (T1D) and T2D are two major types of diabetes. T1D is characterized by a reduction in insulin release from the pancreatic b-cells, while T2D is caused by islet b-cell dysfunction in response to insulin resistance. This review describes the miRNAs that control insulin release and production by regulating cellular membrane electrical excitability (ATP:ADP ratio), insulin granule exocytosis, insulin synthesis in b-cells, and b-cell fate and islet mass formation. This review also examines miRNAs involved the insulin resistance of liver, fat, and skeletal muscle, which change insulin sensitivity pathways (insulin receptors, glucose transporter type 4, and protein kinase B pathways). This review discusses the potential application of miRNAs in diabetes, including the use of gene therapy and therapeutic compounds to recover miRNA function in diabetes, as well as the role of miRNAs as potential biomarkers for T1D and T2D.

show abstract

Section: Pkb (Akt) Signaling (Insulin Sensitivity)mentioning

confidence: 99%

Application of microRNAs in diabetes mellitus

Chen¹,

Lan²,

Roukos³

et al. 2014

Journal of Endocrinology

107

View full text Add to dashboard Cite

show abstract

“…28,62 miR-326 expression is significantly increased in peripheral blood mononuclear cells (PBMCs) from T1D patients; the elevated levels correlate with ongoing islet autoimmunity and the disease severity. 63 Several possible target genes of miR-326, including vitamin D receptor and erythroblastosis virus E26 oncogene homolog 1, are vital modulators of the immune system, suggesting that the miRNA probably has important effects on autoimmunity in T1D by targeting these genes. 63 Another study performed by Yang et al 64 identified 26 differentially expressed miRNAs in PBMCs from newly diagnosed T1D patients, among which miR-146 was the most downregulated molecule.…”

Section: Mirnas: Regulators Of Immune Pathogenesis In T1dmentioning

confidence: 99%

“…63 Several possible target genes of miR-326, including vitamin D receptor and erythroblastosis virus E26 oncogene homolog 1, are vital modulators of the immune system, suggesting that the miRNA probably has important effects on autoimmunity in T1D by targeting these genes. 63 Another study performed by Yang et al 64 identified 26 differentially expressed miRNAs in PBMCs from newly diagnosed T1D patients, among which miR-146 was the most downregulated molecule. The study also showed that the miR-146 levels were associated with ongoing islet autoimmunity.…”

Section: Mirnas: Regulators Of Immune Pathogenesis In T1dmentioning

confidence: 99%

“…The increase in miR-326 expression correlates with ongoing islet autoimmunity and may serve as a candidate biomarker for the autoimmune process in T1D. 63 Yang et al identified 26 miRNAs and 1218 genes that were differentially expressed in PBMCs from newly diagnosed T1D patients. miR-146 was one of the most downregulated molecules and was linked to ongoing islet autoimmunity in T1D patients.…”

Section: Mirnas: Participants In Autoimmunity-mediated β-Cell Damagementioning

confidence: 99%

See 1 more Smart Citation

miRNAs: novel regulators of autoimmunity-mediated pancreatic β-cell destruction in type 1 diabetes

2017

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are a series of conserved, short, non-coding RNAs that modulate gene expression in a posttranscriptional manner. miRNAs are involved in almost every physiological and pathological process. Type 1 diabetes (T1D) is an autoimmune disease that is the result of selective destruction of pancreatic β-cells driven by the immune system. miRNAs are also important participants in T1D pathogenesis. Herein, we review the most recent data on the potential involvement of miRNAs in T1D. Specifically, we focus on two aspects: the roles of miRNAs in maintaining immune homeostasis and regulating β-cell survival and/or functions in T1D. We also discuss circulating miRNAs as potent biomarkers for the diagnosis and prediction of T1D and investigate potential therapeutic approaches for this disease.

show abstract

“…Levels of miR-326 were measured in peripheral blood lymphocytes from type 1 diabetic patients [49]. Note that these miRNAs were extracted from whole blood samples and were in fact associated with blood cells.…”

Section: Circulating Mirnas As Biomarkers Of the Disease Processmentioning

confidence: 99%

Circulating microRNAs and diabetes: potential applications in medical practice

et al. 2015

View full text Add to dashboard Cite

The explosive increase in the worldwide prevalence of diabetes over recent years has transformed the disease into a major public health concern. While diabetes can be screened for and diagnosed by reliable biological tests based on blood glucose levels, by and large there are no means of detecting at-risk patients or of following diabetic complications. The recent discovery that microRNAs are not only chief intracellular players in many biological processes, including insulin secretion and action, but are also circulating, has put them in the limelight as possible biological markers. Here we discuss the potential role of circulating microRNAs as biomarkers in the context of diabetes and its associated complications.

show abstract

Increased expression of microRNA miR‐326 in type 1 diabetic patients with ongoing islet autoimmunity

Cited by 121 publications

References 20 publications

Application of microRNAs in diabetes mellitus

Application of microRNAs in diabetes mellitus

miRNAs: novel regulators of autoimmunity-mediated pancreatic β-cell destruction in type 1 diabetes

Circulating microRNAs and diabetes: potential applications in medical practice

Contact Info

Product

Resources

About